Broad Clinical Laboratories
Broad Clinical Laboratories is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Sponsor Akero Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- The study enrolled 164 participants at 51 investigative sites in France, Italy, Poland, the United States, and Canada between 13 October 2020 and 6 October 2025.
- Enrollment was highest in France (48 participants), followed by Italy (42), Poland (34), the United States (28), and Canada (12).
- There were no substantial modifications or global trial interruptions.
These findings describe the trial, not the service provider’s performance or responsibility.
Questions about this trial experience
What services are recorded for Broad Clinical Laboratories?
The 2026-10-09 snapshot links Broad Clinical Laboratories to 2 distinct CTIS trials. Recorded services include Genetic Testing, DNA Analysis, NGS and RNA sequencing, NGS panel development. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Broad Clinical Laboratories?
The most frequently recorded therapeutic areas are Haematological Malignancies, Hepatology, Metabolic Disorders. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Broad Clinical Laboratories conducted?
The linked trials record locations in 8 countries, including Italy, Poland, Belgium, Germany, Denmark. These are trial locations, not confirmed office locations or countries where Broad Clinical Laboratories delivered services.
What can this page tell me about Broad Clinical Laboratories's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Broad Clinical Laboratories. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Broad Clinical Laboratories LLC